Genelux Corporation, with the ticker symbol GNLX, is an esteemed biopharmaceutical company with a primary focus on the development and commercialization of personalized, oncology medicines using their innovative and proprietary platform, the OncPlex™ Platform.
The OncPlex™ is an all-encompassing platform that has the ability to engineer a variety of oncolytic viruses for unique targeting of various cancers, and specific biomarker detection, critical capabilities in personalized therapeutics. The technology uses light-emitting systems combined with advanced diagnostic next-generation sequencing approaches to enable precise cancer localization, identification of functional genomic alterations, and more importantly, to monitor cancer treatment in real-time. This platform is unique to the Genelux and is the backbone of their ambitions to advance precision oncology.
Genelux’s primary focus and flagship work have been in Onco-imaging, specifically developing Olvi-Vec (Oncolytic Vaccinia Virus), a proprietary oncolytic vaccinia virus. Vaccinia Virus is a poxvirus known for its use as a vaccine that eradicated smallpox worldwide. Genelux has genetically modified the Vaccinia Virus to replicate exclusively in cancer cells, leading to their destruction and creating the ability to visualize or image tumors in cancer patients, an advancement that could revolutionize cancer diagnosis and treatment.
Genelux Corporation was founded in 2001 by Dr. Aladar A. Szalay, and since then, it has grown to become a major force in the global pharmaceutical and healthcare industry. The company has raised over $237 Million in funding, emphasizing the high level of investor confidence and influence of the company. They are headquartered in San Diego, California, and continue to be a leader in personalized therapies for cancer through a variety of innovative and specifically designed therapeutics.
Despite being a privately-owned company, Genelux Corporation is recognized as a dominant player in the pharmaceutical industry, with its progressive approach to cancer treatments, and innovative biochemical engineering. All these attributes contribute to making this corporation a promising participant in the fight towards finding advanced, patient-centered treatments for cancer. Genelux has the potential to change the landscape of cancer treatment globally, offering advanced alternative treatments for a disease that affects millions worldwide.